Additive effect of P2X3 inhibitor, gefapixant, on azelastin for refractory atopic cough

Additive effect of P2X3 inhibitor, gefapixant, on azelastin for refractory atopic cough - Additive effect of P2X3 inhibition for refractory atopic cough

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058428

Enrollment

Registered

2025-09-30

Start date

2022-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic cough

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Refractory atopic cough

Exclusion criteria

Exclusion criteria: (1) Patients with unstable comorbidities (2) Other patients deemed inappropriate as research subjects by the principal investigator

Design outcomes

Primary

Measure	Time frame
cough sensitivity for capsaicin inhalation	—

Secondary

Measure	Time frame
visual analog score of cough The Leicester Cough Questionnaire (LCQ)	—

Countries

Japan

Contacts

Public ContactYOSHIHISA ISHIURA

Kansai Medial University Respiratory and Allergy Medicine,

ishiuray@takii.kmu.ac.jp09089686294

Outcome results